ALG-135041 / Aligos Therap - LARVOL DELTA

Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma (EASL-ILC 2023) - "SSO in vivo efficacy (10 x 15 mg/kg or 10 x 30 mg/kg, SC, QOD) was carried out in a Hep3B-luc orthotopic mouse model with the positive control sorafenib (20 x 60 mg/kg, PO, QD). ALG-135041, a human β-catenin SSO, selectively inhibits DNA transactivation activity in the nucleus and showed a better therapeutic window than either siRNAs or ASOs. We therefore significantly improved the therapeutic window by precision targeting of only the disease-causing region of the multifunctional protein β-catenin."

Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Oncology • Solid Tumor • CCND1 • CDH1 • MYC